Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
RegulatoryapprovedRhapsido®Positive
AI Analysis
Summary
Novartis announced FDA approval of Rhapsido® (remibrutinib) for symptomatic dermographism, marking the first approved treatment for this condition in adults inadequately controlled by H1 antihistamines. The approval expands the drug's therapeutic use beyond its previous indication of chronic spontaneous urticaria.
Outcome Details
FDA approval for symptomatic dermographism in adults inadequately controlled by H1 antihistamines
Importance:8/10
Sentiment:
0.90
FDA approvaldermatologyfirst-in-classindication expansionBTKi
Related Companies
Read the original article
Published by GlobeNewswire Pharma on October 7, 2026 3:45 PM